234 A phase 1, open-label, dose-finding study to assess the safety and tolerability of {U3} 1287 (AMG 888), a human monoclonal antibody targeting {HER3} in patients with advanced solid tumors

P. LoRusso; V. Keedy; L. Yee; M. Oliveira; N. Rizvi; J. Berlin; X. Jin; T. Hettmann; C. Copigneaux; D. Beaupre

首页> 外文期刊>European Journal of Cancer Supplements >234 A phase 1, open-label, dose-finding study to assess the safety and tolerability of {U3} 1287 (AMG 888), a human monoclonal antibody targeting {HER3} in patients with advanced solid tumors

【24h】

234 A phase 1, open-label, dose-finding study to assess the safety and tolerability of {U3} 1287 (AMG 888), a human monoclonal antibody targeting {HER3} in patients with advanced solid tumors

机译：234 A期1期，开放标签，剂量寻找研究，用于评估 {U3 } 1287（AMG 888）（一种针对 {HER3 }的人类单克隆抗体）在晚期实体瘤患者中的安全性和耐受性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2010年第7期|共页
作者
P. LoRusso; V. Keedy; L. Yee; M. Oliveira; N. Rizvi; J. Berlin; X. Jin; T. Hettmann; C. Copigneaux; D. Beaupre;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
专利

1. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. [J] . Hiroshi Wakui, Noboru Yamamoto, Shinji Nakamichi, Cancer chemotherapy and pharmacology. . 2014,第3期

机译：在日本患有晚期实体瘤的患者中，针对HER3的人类单克隆抗体patritumab（U3-1287）的第一阶段和剂量确定研究。
2. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. [J] . Hiroshi Wakui, Noboru Yamamoto, Shinji Nakamichi, Cancer chemotherapy and pharmacology. . 2014,第3期

机译：Patritumab（U3-1287），靶向HER3的人类单克隆抗体的阶段1和剂量查找研究，在日本患有先进的晚期实体瘤患者中。
3. Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors [J] . LoRussoP., J?nneP.A., OliveiraM., Clinical cancer research: an official journal of the American Association for Cancer Research . 2013,第11期

机译：U3-1287（一种完全人源抗HER3单克隆抗体）在晚期实体瘤患者中进行的I期研究
4. Phase 1 and dose-finding study of patritumab (U3-1287) a human monoclonal antibody targeting HER3 in Japanese patients with advanced solid tumors [O] . Hiroshi Wakui, Noboru Yamamoto, Shinji Nakamichi, -1

机译：在日本患有晚期实体瘤的患者中针对HER3的人单克隆抗体patritumab（U3-1287）的第一阶段和剂量确定研究
5. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors [O] . Hiroshi Wakui, Noboru Yamamoto, Shinji Nakamichi, 2014

机译：在日本患有晚期实体瘤的患者中，针对HER3的人单克隆抗体patritumab（U3-1287）的第一阶段和剂量确定研究

234 A phase 1, open-label, dose-finding study to assess the safety and tolerability of {U3} 1287 (AMG 888), a human monoclonal antibody targeting {HER3} in patients with advanced solid tumors

著录项

相似文献

相关主题

期刊订阅